Global stocks are rising moderately as investors wait for a vote on American healthcare. Tomorrow there will be a vote in Congress on Republican healthcare bill. This vote is seen as the first test of Trump’s ability to pursue his agenda and in case of a success, reflation trade will likely resume. S&P 500 futures are 0.1% higher; Eurostoxx 600 is 0.2% up. The dollar DXY index is slightly up. US 10Y treasury yields are up 1 bp at 2.41% falling 6 bp from the start of the week.
Oil prices declined on a built up in crude oil stockpiles. Inventories increased by 5.0 mn bbl (higher than consensus forecast of a 2.8 mn bbl rise). Brent prices are 0.4% lower at $50.5/bbl.
Russia and CIS area developments and market colour
The rouble is 0.4% stronger today at 57.5 versus USD. OFZ yields are 2-7 bps wider today. Russia’s and Kazakhstan’s longer term sovereign yields are 1-2 bps and 3-5 bps tighter today.
Putin proposed to nominate Central bank Governor Nabiullina for a new term. Nabiullina has held an office since 2013 with her term expiring in June. The news means that relatively tight monetary policy will be retained.
Gazprom has announced that it will hold a road show of sterling Eurobonds on March 27. The company plans to issue a medium term debt. Earlier in March Gazprom has placed 10Y Eurobonds with YTM at 4.95%.
Brazil’s energy giant, Petrobras, announced financial results for 4Q 2016. The results are improved compared to 4Q 2015 and the previous quarter. In 2015, the news broke that Petrobras was involved in the biggest corruption scandal, and now the company is actively restructuring the business and selling assets. During the last two years assets worth $13.6 billion were sold, and it is planned to sell $21 billion of assets until 2018.
Despite sales staying constant at around 70.4 billion reais, net income reached 2.51 billion reais ($762.8 million) in 4Q 2016. During the same period last year, the company reported a record loss of 36.94 billion reais ($9.6 billion). The loss for 2016 stood at 14.82 billion reais falling 57.4% YoY. It has to be stressed that EBITDA substantially rose 2.5 times YoY to 65.65 billion reais ($18.95 billion). Net debt declined 20% to 314 billion reais ($96.42 billion) last year. As a result, Net debt/EBITDA during the year decreased from 14.96% to 4.78%.
For more information on the research, please click here.
Norvik Banka Research
+44 207 259 8854
+371 6701 1561
This report is prepared by Norvik Banka UK Limited, of 46-48 Grosvenor Gardens, London, SW1W 0EB, United Kingdom (hereinafter referred to as the Company) as a marketing communication for information purposes only. Neither the information nor any opinion contained in this report (notwithstanding the source) is intended to be, or should be construed as an offer, a recommendation, an advice or an invitation to make an offer, to buy or sell any financial instrument. Information contained in this report constitutes neither investment nor tax advice and it does not take into account the specific investment objectives, risk appetite and financial situation of anyone who may receive this report. Investors should seek their own advice regarding the appropriateness of investing in any financial instrument discussed in this report and carefully evaluate the risks and eventual losses that are related to the investment services and its compliance with their investment goals.
Investors should note that any income derived from investments in financial instruments may fluctuate and that the price or value of securities and investments may rise or fall. Accordingly, investors may lose their investment or receive back less than originally invested. Past performance and income is not a guide to future performance and income. Foreign currency exchange rates may adversely affect the value, price or income of any security or related investment mentioned in this report. Investing in the Russian or CIS economies and securities involves a high degree of risk and requires appropriate knowledge and experience.
The information contained in this report have been obtained from such public sources what are believed to be reliable, but no representation or warranty is made by the Company with regard to accuracy. Therefore the information contained herein is subject to change without prior notice.
This report should not be viewed as the only source of information, and neither the Company, nor the companies within the NORVIK group and/or any affiliates or employees thereof accept any responsibility or liability whatsoever for any direct or indirect damage arising out of or in any way connected with the use of information contained herein, nor for its authenticity.
This report may not be distributed, copied, reproduced or changed without prior written consent from the Company. Further information, which for the avoidance of doubt cannot be treated as the recommendations and/or advice either, may be obtained from the Company upon request.
This report has not been prepared on the basis of the requirements of regulatory provisions promoting independence of investment research and is not subject to the prohibition from making transactions before disseminating investment research.
Norvik Banka Research is a Trading Name of Norvik Banka UK Ltd, which is Authorised and Regulated by the Financial Conduct Authority, FRN: 681329. Registered in England and Wales with number 08940522. Registered Office: 46/48 Grosvenor Gardens 1st Floor, London, SW1W 0EB.
The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.
This email has been scanned for viruses and malware, and may have been automatically archived by Mimecast Ltd, an innovator in Software as a Service (SaaS) for business. Providing a safer and more useful place for your human generated data. Specializing in; Security, archiving and compliance. To find out more Click Here.